Palvella Therapeutics PVLA Interest Income Expense Nonoperating Royalty Agreement
Interest Income Expense Nonoperating Royalty Agreement at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept pvla:InterestIncomeExpenseNonoperatingRoyaltyAgreement.
The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Palvella Therapeutics's interest income expense nonoperating royalty agreement.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Palvella Therapeutics's interest income expense nonoperating royalty agreement?
- Palvella Therapeutics (PVLA) reported interest income expense nonoperating royalty agreement of -$2.04M in Q1 2026.
- How has Palvella Therapeutics's interest income expense nonoperating royalty agreement changed year-over-year?
- Palvella Therapeutics's interest income expense nonoperating royalty agreement decreased by 67.8% year-over-year, from -$1.22M to -$2.04M.
- What does interest income expense nonoperating royalty agreement mean?
- This represents non-operating financial obligations or income derived from royalty agreements linked to intellectual property or product commercialization rights. It captures the impact of contractual royalty payments or receipts that fall outside of core operational revenue and expense categories. Investors use this to assess the financial burden or benefit of external licensing arrangements.